Mutations in the quinolone resistance-determining regions (QRDR) in chromosomal gyrA and parC genes and fluoroquinolone susceptibility profiles were investigated in quinolone-resistant Enterobacteriaceae 
INTRODUCTION
Fluoroquinolones have been frequently prescribed as empirical therapy against most hospital and community infections due to increased appearance of multiple drug resistant Gram-negative pathogens and to the disease severity (2, 8, 22) . In countries with extensive clinical use of quinolones, fluoroquinolone resistance has been a problem in clinical medicine for its limiting of available agents in the treatment of many types of infection (1, 7, 15, 23) . QepA and OqxAB, belonging to the major facilitator superfamily (MFS) transporters (6, 27) . Topoisomerase mutations have not been, up to now, systematically investigated and explored in clinical isolates from Brazil, except in a report on ciprofloxacin susceptible E. coli (5) .
The objective of this study was to assess the presence of mutations in the QRDR of chromosomal gyrA and parC genes and fluoroquinolone susceptibility profile in quinoloneresistant Enterobacteriaceae isolated from community and hospital patients in the Brazilian Southeast region. 
MATERIALS AND METHODS

Bacterial isolates and susceptibility testing
Detection of mutations in the topoisomerase genes
DNA extraction and PCR analysis were performed as described elsewhere using sets of primers designed for amplification and sequencing of topoisomerase genes (10).
DNA was amplified using an initial denaturation step of 5 min 
RESULTS AND DISCUSSION
Species distribution among the 112 Enterobacteriaceae isolates was: Escherichia coli (n=65), Klebsiella pneumoniae
Citrobacter freundii (n=2), Providencia stuartii (n=2), Serratia marcescens (n=2), Enterobacter aerogenes (n=1) and Proteus QRDR mutations in Enterobacteriaceae mirabilis (n=1). Twenty-three percent of the 112 nalidixic acidresistant isolates were susceptible to ciprofloxacin and/or levofloxacin (MIC ≤ 1 µg/mL). * qnrA gene present † CIP, ciprofloxacin, NOR, norfloxacin; OFL, ofloxacin; LVX, levofloxacin ‡ Susceptibility (≤ value) and resistance (≥ value) breakpoints defined by CLSI (2011): 4 µg/mL and 16 µg/mL for norfloxacin, 2 µg/mL and 8 µg/mL for levofloxacin and ofloxacin, 1 µg/mL and 4 µg/mL for ciprofloxacin.
According to Ruiz (21) 
